Now more than ever, companies may need to consider agile and novel evidence generating study designs to streamline development. How do we balance the need to pursue more rapid but unconventional research approaches to identify treatments for Covid with the risk of generating erroneous results? This webinar analyzes the role that Real-World Evidence (RWE) is playing in supporting the urgent need for evidence on emerging therapies for COVID-19.
This webinar will cover:
- Early experience with CTAP and other regulatory mechanisms
- How EMR and other data providers are responding to the need for real-time data on patient treatment and outcomes in COVID-19 and how to navigate them
- The value and challenges of synthetic control arms in COVID-19 research
- How COVID-19 is going to shape RWE’s role in drug development going forward
Featured Speakers
Leanne Larson
Corporate Vice President & WW Head Real-World Evidence
Parexel
Michelle Hoiseth
Senior Vice President & Chief Data Officer
Parexel